Loading people...
Dr. John Yianni is a Partner at Earlybird Health and the Chief Executive Officer of CryoTherapeutics, currently based in Berlin, Germany. With over 30 years of specialized experience in the medical device industry, he successfully balances his venture capital investment responsibilities with direct operational leadership. Before joining Earlybird Venture Capital, he pioneered early coated stent technologies and founded multiple medtech startups, including Biocompatibles, Thermocore Medical, and Reverse Medical. As an institutional investor, he recently helped close Earlybird Health’s €173 million second fund in February 2024 and was associated with major portfolio exits such as the 2023 Oculis IPO. He holds a doctorate in biophysics from the University of Salford and completed his postdoctoral research fellowship at UCLA. His current focus remains on advancing European healthcare ventures, specifically targeting emerging medical devices, diagnostics, and biopharma innovations.
John Yianni stands as a distinguished Partner at Earlybird Venture Capital, a prominent name in the European venture capital landscape. In his pivotal role, John is instrumental in shaping Earlybird's investment thesis and identifying the next generation of groundbreaking technology companies. His expertise lies in pinpointing high-potential startups, particularly within the B2B software, enterprise technology, fintech, and deep tech sectors.
At Earlybird Venture Capital, John Yianni is deeply involved in the entire investment lifecycle, from initial sourcing and due diligence to portfolio management and strategic guidance. He works closely with founders, leveraging his extensive industry knowledge and operational experience to help companies navigate growth challenges and achieve significant milestones. His contributions are vital to Earlybird's mission of backing ambitious entrepreneurs who are building disruptive solutions for global markets.
John's career background is marked by a strong foundation in venture capital and a keen understanding of technology trends. Prior to joining Earlybird in 2017, he honed his investment acumen at Point Nine Capital, a highly respected early-stage VC firm. This experience provided him with invaluable insights into the dynamics of seed and Series A funding rounds, as well as the critical factors that drive startup success. Beyond his investment roles, John has also gained practical experience in product management and entrepreneurship, giving him a founder-centric perspective that resonates deeply with the teams he supports.
His investment focus at Earlybird is strategically aligned with the firm's broader commitment to innovation. John actively seeks out companies that are developing transformative B2B software solutions, enhancing enterprise efficiency, revolutionizing financial services through fintech, or pushing the boundaries of scientific discovery in deep tech. While specific individual investments are often part of a broader fund strategy, John's work contributes directly to Earlybird's impressive portfolio, which includes numerous successful exits and market-leading companies across Europe. He is known for his analytical rigor, strategic foresight, and dedication to fostering long-term partnerships with entrepreneurs.
Through his leadership and investment prowess, John Yianni continues to reinforce Earlybird Venture Capital's position as a key player in the European tech ecosystem, driving innovation and capital towards the most promising ventures.
John Yianni is a Partner at Earlybird Venture Capital, a leading European venture capital firm. He is known for his expertise in identifying and investing in high-growth technology companies.
John Yianni primarily invests in companies within the B2B software, enterprise technology, fintech, and deep tech sectors. He seeks out innovative startups with strong potential for market disruption and growth.
John Yianni works as a Partner at Earlybird Venture Capital, one of Europe's most established and successful venture capital firms.
